Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world. While the company provides some of the most technologically advanced products in the industry, everything is driven by the fundamental belief that “the beauty of science is to make things simple.”
Veneno Technologies Co. Ltd.
Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels, GPCRs, and transporters. | Veneno Technologies is a Japan-origin deep-tech biotech company founded in 2020 and built around a proprietary Disulfide-Rich Peptide, or DRP, discovery platform. Based on scientific achievements originating from AIST, the company has established an integrated end-to-end system combining design, screening, functional evaluation, and production of DRPs through its proprietary Veneno Suite and PERISS platform. Veneno aims to create a new peptide modality for targets that have remained difficult to address with conventional small molecules or antibodies. The company’s core strength lies in its ability to translate the intrinsic biological advantages of naturally occurring DRPs into an industrial discovery engine. Because DRPs possess multiple disulfide bonds and a conformationally constrained structure, they can offer high stability, protease resistance, thermal robustness, and strong target selectivity. These properties make DRPs especially attractive for membrane proteins and other challenging target classes where conventional modalities often face limitations in selectivity, penetration, or functional control. Veneno is leveraging this differentiated biology to generate novel therapeutic candidates with the potential to open new mechanisms of action in previously hard-to-drug disease areas. Current Strategic Focus Areas 1) Ri-DRP drug discovery: Veneno is actively advancing Ri-DRP programs in which DRPs are conjugated with radioactive payloads, including alpha-emitting isotopes. By combining the high target selectivity and compact size of DRPs with radiopharmaceutical design, the company aims to enable precise tumor targeting and differentiated payload delivery beyond what is often achievable with conventional antibody-based radioconjugates or small-molecule radiopharmaceuticals. Ri-DRP represents a highly strategic direction for Veneno, particularly in oncology, where target-specific delivery, tissue distribution, and therapeutic precision are central to next-generation drug design. 2) Functional development of DRPs as next-generation antibody-like molecules: Veneno positions DRPs not simply as peptides, but as a next-generation functional modality that can complement and, in selected settings, outperform antibodies. The compact and highly structured nature of DRPs allows precise interaction with biologically important surfaces while maintaining strong stability and selectivity. This creates opportunities in areas where antibodies may be constrained by tissue penetration, epitope accessibility, or molecular size. Veneno is therefore developing DRPs as next-generation antibody-like agents for membrane proteins, complex interaction interfaces, and disease areas that require finely tuned molecular recognition. 3) DRP drug discovery for membrane proteins including ion channels, GPCRs, and transporters: Veneno’s discovery platform is particularly differentiated in the generation of functional DRPs against membrane proteins that have historically been difficult to drug. Through the proprietary PERISS method, the company can identify inhibitor, activator, and binder DRPs for ion channels, GPCRs, transporters, and related membrane targets. These target classes are biologically important across oncology, inflammation, pain, cardiometabolic disorders, and other major therapeutic areas, yet they remain challenging because small molecules can suffer from off-target effects and antibodies often have limited access to the relevant target surfaces. Veneno is using DRPs to bridge this gap and unlock first-in-class opportunities in membrane protein drug discovery. Through these three focus areas, Veneno Technologies is positioning DRPs as a scalable platform for next-generation therapeutics spanning membrane protein drug discovery, antibody-like functional molecules, and radiopharmaceutical innovation. At BIO International 2026, the company is seeking global collaboration opportunities including joint research, co-development, licensing, and strategic partnerships with pharmaceutical companies, biotech innovators, radiopharmaceutical developers, and research institutions.
Vacino Biotech Co., Ltd.
Vacino Biotech focuses on innovations for HLA-peptide based vaccine (9-mer peptide), nucleic acid medicine (microRNA) and brain delivery technology (targeting peptide) for the indication of infectious disease, neurodegenerative disease and oncology. Core products: Oral universal COVID vaccine against SARS-CoV-2 variants A microRNA-based anti-neuroinflammation therapeutics A brain shuttled anti-Her2 antibody for treating the peripheral and intracranial tumors. An oral bioavailable brain-targeting LNP for delivering the oligonucleotide and large molecule therapeutics Show less Description (NOTE: Given time constraints & strategic priorities, we will not be meeting with CMOs, CROs, service companies, etc. at the meeting) Founded in July 2020, Vacino Biotech is committed to the development of novel nucleic acid drugs and universal vaccines. With the self-developed next-generation vaccine design SED technology, we have invested in the development of COVID-19 T-cell vaccine products to solve the situation of rapid mutation of the new coronavirus variants. In addition, it has invested in the development of nucleic acid drugs for the treatment of Alzheimer’s disease and a cutting-edge efficient brain delivery technology to increase the content of brain treatment drugs and prevent the occurrence of diseases at an early stage. ● Core products and platform technology Oral universal COVID-19 vaccine: VACINO-CO is a novel oral universal antigen vaccine designed to protect against most COVID-19 viruses and related variants. Through the activation of T cells, it can eliminate virus-infected cells, which can effectively inhibit recurrence and the phenomenon of seroconversion. The innovative and convenient oral dosage form can be applied to the elderly and children in vulnerable groups to obtain safer and effective immunity, safe and effective immune protection of the population. It is currently about to enter human clinical trials. MicroRNA-based Alzheimer’s Disease Drug Developments: Patented Vacino-ADmir is a microRNA-based drug that inhibits neuroinflammation through the PD1/PDL1 mechanism associated with inflammation and can be treated from the source of the disease, which is different from the symptomatic treatment on the market. It can be applied to dementia and neuroinflammation-related diseases. GMP manufacturing is currently underway. High-Performance Brain Delivery Platform Technology: The patented Vacino-BT target peptide can be co-transported by binding to transferrin receptors through transcytosis, with a brain delivery rate of more than 20 % a 1-hour post-injection, which is far superior to other brain delivery technologies on the market. At present, it has been successfully applied to antibodies and lipid nanoparticles. GoBrain LNP: Based VBT technology, we developed VBT-lipid conjugates that can enable LNP having brain targeting capability. HerBrain and eHerbrain platform: Based on VBT technology, we developed chemically modified anti-Her2 antibody and novel DNA-engineered anti-Her2 antibody, which allows brain shuttle capability and tissue penetration.
Sussex Research Laboratories Inc.
Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in empowering therapeutic innovation through glycoscience. The company applies its expertise in glycodesign, glycan and glycoconjugate synthesis, and linker chemistries across a wide range of therapeutic areas, including vaccine development, protein and antibody engineering, and targeted drug delivery. With 30 years of experience as a Contract Research & Development (CRO) service provider, Sussex Research supports pharmaceutical and biopharmaceutical partners in applying glycotechnology to next-generation therapeutics, including oligonucleotide, peptide, protein, lipid, and small-molecule modalities, as well as lipid nanoparticle (LNP) technologies for modern drug design and delivery. The company is also widely recognized for its enabling product portfolio of advanced glycans, glycopeptides, glycoconjugates, and targeting ligand/linker systems.
Simpson Biotech Co., Ltd.
Simpson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used for dietary supplements, cosmetics & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag. New product launched in 2023: 1. Antrodia cinnamomea extract as natural ingredient for cosmetics formulation, 2. Potent anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; 2. World’s first high purity (chitobiose+chitotriose > 90%) oligo chitosan for weight, diabetes and triglyceride control; 3. Hydrolyzed Fucoidan for immune & glucose control. SBC has won numerous awards with 54 patents issued. —–>—– 【Natural Compound as Oral Drug development for NAFLD/NASH】 Reduce liver triglyceride and cholesterol in NAFLD Reduce serum triglyceride and cholesterol in NAFLD Reduce liver fat deposition in NAFLD Reduce ALT and AST in NAFLD Anti-inflammation and oxidative stress Anti-fibrosis US, CN, TW patents granted 【Recombinant Protein Expression/Purification Platform (HERPEPSTM) and Products】 Patent Recombinant Protein Platform & CDMO Service – Cost-effective recombinant protein expression & purification system; From gene to protein Starch Binding Protein (SBP) as an affinity tag One-step purification of recombinant protein by starch Protein immobilization on starch enhanced the thermostability & shelf life Easy to scale up: From 100L lab-scale concept proof to 8000L mass production Ideal for industrial, food, feed enzymes Self-owned Tool Box for Protein Expression in Pichia pastoris Methanol-induced or Methanol-free expression Antibiotics-free expression host Genetic manipulation of expression strain with high yield Cost can be 12%) of Simpson Biotech’s currently marketed dietary supplement actually illustrates both the safety and the effectiveness of the mycelia and the compound of Hepasim® through human clinical studies. One clinical study for Rheumatoid Arthritis (RA) has been completed. Initial results from the clinical study plus the previous metabolic/pharmacokinetic animal studies on these compounds already illustrate that Hepasim® is a promising NCE drug candidate. 【Fermented natural products for dietary supplement】 Alcoholic Hangover Release : Antrodia cinnamomea mycelia Neuroprotective & Memory Enhancement : Ginsenoside compound K Immune Regulation : Cordyceps sinensis mycelia, Hydrolyzed Fucoidan Male Hormone (Testosterone) Stimulant : Cordyceps sinensis mycelia Heart Protection : Agaricus blazei murill Increase Stamina : low molecular weight functional peptides from casein, whey, soy, collagen, silk OEM/ODM Fermentation : Cordyceps sinensis, Phellinus linteus, Ganoderma lucidum, Agaricus blazei murill and other mycelia and their extracts Fermented Vegetables & Grains Concentrate as prebiotics Cosmetics for skin whitening & anti-scar : Antrodia cinnamomea extract 【Immune booster for IFN-γ stimulation as anti-viral and antibiotic alternative feed additive】 LZ-8 is a fungal immunomodulatory protein originally isolated from the popular oriental medicinal fungus. Oral administration of rLZ-8 stimulates IFN-γ secretion. It is not only a good dietary supplement for humans but also an antibiotic alternative for animal additives for the prevention of virus or coccidia infection in field studies. Possible pharmaceutical applications per oral include immune-regulatory diseases. IFN-γ Stimulant Anti-viral Antibiotic alternative Anti-coccidia Increase feed efficiency US, TW, CN patent granted (US9950028, I589586, CN106232133A) | Simpson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used for dietary supplements, cosmetics & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag and in-house non-methanol, antibiotics-free expression strain. Highlight in 2024: 1. Recombinant protein OEM/ODM with proprietary yeast platform, 2. Antrodia cinnamomea extract as natural ingredient for cosmetics formulation. 3. Antrodin as potent oral drug for NAFLD/NASH; 4. Natural anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; SBC has won numerous awards with 54 patents issued. —–>—– 【Recombinant Protein OEM/ODM with Proprietary Yeast Platform】 – One-step purification of recombinant protein by starch – Protein immobilization on starch enhanced the thermostability & shelf life – Easy to scale up: From 100L lab-scale concept proof to 8000L mass production – Ideal for industrial, food, feed enzymes – Turn-key licensed(non-exclusive) to global feed company already > – In-house Non-Methanol promoter compared to AOX1 – Antibiotics-free expression strain: Eco-friendly – Genetic manipulation of expression strain with high yield – Cost can be 12%) of Simpson Biotech’s currently marketed dietary supplement actually illustrates both the safety and the effectiveness of the mycelia and the compound of Hepasim® through human clinical study for Rheumatoid Arthritis (RA). – Initial results from the clinical study plus the previous metabolic/pharmacokinetic animal studies on these compounds already illustrate that Hepasim® is a promising NCE drug candidate. 【Fermented natural products for dietary supplement】 – Alcoholic Hangover Release : Antrodia cinnamomea mycelia – Neuroprotective & Memory Enhancement : Ginsenoside compound K – Immune Regulation : Cordyceps sinensis mycelia, Hydrolyzed Fucoidan – Male Hormone (Testosterone) Stimulant : Cordyceps sinensis mycelia – Heart Protection : Agaricus blazei murill – Increase Stamina : low molecular weight functional peptides from casein, whey, soy, collagen, silk – OEM/ODM Fermentation : Cordyceps sinensis, Phellinus linteus, Ganoderma lucidum, Agaricus blazei murill and other mycelia and their extracts – Fermented Vegetables & Grains Concentrate as prebiotics – Cosmetics for skin whitening & anti-scar : Antrodia cinnamomea extract 【Immune booster for IFN-γ stimulation as anti-viral and antibiotic alternative feed additive】 LZ-8 is a fungal immunomodulatory protein originally isolated from the popular oriental medicinal fungus. Oral administration of rLZ-8 stimulates IFN-γ secretion. It is not only a good dietary supplement for humans but also an antibiotic alternative for animal additives for the prevention of virus or coccidia infection in field studies. Possible pharmaceutical applications per oral include immune-regulatory diseases. – IFN-γ Stimulant – Anti-viral – Antibiotic alternative – Anti-coccidia – Increase feed efficiency – US, TW, CN patent granted (US9950028, I589586, CN106232133A) | Simpson Biotech Co., Ltd. specializes in bio-fermentation development and commercialization: 1. Medicinal fungi for dietary supplements and early-stage drug discovery, specifically Hepasim®. 2. SimpsonPure health supplements portfolios. 3. Patented platform developing for recombinant protein expression and purification. We are seeking partnerships for the development of new recombinant proteins.
PrecisemAb Biotech Co., Ltd.
PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, can significantly reduce side effects caused by antibody drugs, making antibody therapy safe and effective. [Features of Core Technology (Antibody Lock)] ‧Higher masking ability and removal ability ‧Low immunogenicity ‧Prevention of anti-drug antibody binding ‧Prolonged serum half-life [Lead Product] PSM101, the lead candidate for head and neck cancer and colorectal cancer treatment, will complete stable cell clone generation in 2023 and the non-human primate side effect test in 2024-Q1. [Partnering] Through the (1) co-development of Lock-antibodies and (2) customized Antibody Lock design service, PrecisemAb licenses out Lock-antibodies to global pharma for conducting further clinical trials. | PrecisemAb is a spin-off startup of Kaohsiung Medical University. Its core technology, Universal Antibody Lock, allows antibody drugs, including ADC and bispecific antibodies, to take effect only in diseased areas, solving systemic toxicity and making antibody treatment safe and effective. Now, we are developing the first-in-class antibody drug, PSM101, for advanced head and neck cancer. [Features of Antibody Lock] ★Medication safety with minimized adverse effects ★Elevating treatment efficacy for cancer cure ★Precision-designed for targeting various cancers [Partnering] PrecisemAb licenses Lock-antibodies for further clinical trials through: (1) Co-development of Lock-antibodies: [Oncology] Lock-EGFR, Lock-PD1, Lock-CTLA4, Lock-4-1BB [Autoimmune disease] Lock-TNFα, Lock-IL-1β (2) Customized Antibody Lock Design Service: Including 4 steps to design your own Lock-antibody. | Company Overview Founded in October 2021, PrecisemAb Biotech was established by the late Professor Tian-Lu Cheng, former Vice President of Kaohsiung Medical University (KMU), as a KMU spin-off company. PrecisemAb focuses on applying the exclusively licensed Universal Antibody Lock Technology to develop next-generation precision antibody drugs with high specificity, low side effects, and enhanced therapeutic efficacy. Innovations & Advantages of the Universal Antibody Lock Platform The Universal Antibody Lock Technology integrates a Hinge + Linker structure that connects the VL/VH domains of an antibody. This unique design prevents antibodies from binding to healthy tissues until they reach the tumor microenvironment (TME). The Hinge-based lock, derived from human IgG1, serves as a masking mechanism, reducing unwanted interactions with normal tissues. The Linker, optimized through computational modeling, includes tumor-specific protease cleavage sites and spatial adjustment regions that ensure precise activation in the tumor microenvironment (TME). This mechanism enables antibodies to remain inactive in normal tissues and only activate when exposed to tumor-specific proteases, thereby minimizing off-target toxicity and enhancing therapeutic efficacy. By selectively triggering antibody activation at the tumor site, this technology significantly reduces side effects and improves treatment outcomes, ultimately enhancing patient quality of life. Compared to competing platforms, the Universal Antibody Lock Technology offers several key advantages. First, the human IgG1 hinge-based lock has low immunogenicity, reducing the risk of anti-drug antibody (ADA) formation and avoiding interference with drug efficacy. Second, the platform is highly versatile, allowing seamless integration into monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and bispecific antibodies (BsAbs), which accelerates the development timeline for Lock-antibody drugs. Third, the linker design, incorporating tumor-specific protease cleavage sites and spatial adjustment regions, delivers the highest antibody activation rate globally in TME. The Universal Antibody Lock Technology has been adopted for industry collaboration. In May 2024, GlycoNex Biotech signed a non-exclusive licensing agreement with PrecisemAb, further demonstrating its applicability in antibody drug development. Drug Development (1) PrecisemAb’s lead drug, PSM101 (Lock-EGFR antibody), is designed for EGFR-expressing cancers, including head and neck cancer and colorectal cancer. The drug has successfully completed in vitro and in vivo efficacy and safety studies, cell line development, upstream process optimization (yield: 4.2 g/L), downstream process optimization, formulation research, and accelerated stability testing. PSM101 is planned for IND submission to the US FDA and TFDA in Q4 2026. (2) Additionally, PSM915 (Lock-TNF-α) has been evaluated in Biomedcode’s rheumatoid arthritis (RA) mouse model, demonstrating its ability to suppress RA disease progression and improve drug safety.
Phase Clinical Services
Your complete resource for oncology clinical trials and biospecimens | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies. Our clients are pharma and biotech companies from startup to the top-ten level, assay developers, high-end academic institutions, and the U.S. government. We maintain an FDA-registered cell isolation lab in Milwaukee and an in-house pathology service. | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies.